IL6 and COVID-19: Finally, although this study focused on patients with COVID-19, as peripheral IL-6 levels are increased in diverse infectious and non-infectious systemic conditions, this study lays the foundation for future phase II studies that modulate the IL-6 pathway to ameliorate delirium in varied clinical scenarios.